An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Q4 Results Today May 30, 2025, Highlights: Find all the Q4 results 2025 updates for Apollo Hospitals, Vodafone Idea, Sun TV Network, Bajaj Holdings, Inox Wind Energy, AstraZeneca Pharma and more here.

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

During a live event, Ahmad Tarhini, MD, PhD, moderated a discussion on selection of immunotherapy regimens for patients with ...